Intellia Therapeutics NTLA 深 沪
等待开盘 07-29 09:30:00 美东时间
13.11
-0.485
-3.57%
华盛通- 最 高13.73
- 今 开13.68
- 成交量 389.11万股
- 最 低 12.94
- 昨 收 13.595
- 总市值 13.63亿
- 52周最高 24.16
- 市盈率 静 --
- 换手率 3.74%
- 52周最低 5.90
- 委 比 49.42%
- 总股本 1.04亿
- 历史最高 202.73
- 量 比 0.64
- 振 幅 5.81%
- 历史最低 5.90
- 每 手 1
- 风险率 5.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Insider Sales Shake Up Southern Co, Constellation, Intellia, US Bancorp, and Kohl’s
Insiders have been trading these 5 stocks: (($SO)), (($STZ)), (($NTLA)), (($USB...
07-26 21:01
Arrowhead hits the skids due to partnership with Sarepta
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is down ~22% since market close on July 18 and the reason could be that the company has several early-stage candidates in partnership with recently belaguered S...
07-21 23:58
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease
KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US.
07-07 19:47
Insider Sales Shake Royal Caribbean, Kroger, HP, Intellia, EOG
Insiders have been trading these 5 stocks: (($RCL)), (($KR)), (($HPE)), (($NTLA...
07-05 21:02
Pure Storage's new CFO gets praise from analysts
Pure Storage's (NYSE:PSTG) announcement on Tuesday that Tarek Robbiati will become its new Chief Financial Officer has received praise from some Wall Street analysts. Evercore ISI analyst Amit Daryan...
06-25 03:45
Pure Storage announces CFO appointment
Pure Storage (NYSE:PSTG) has named Tarek Robbiati as its new chief financial officer, effective immediately. Robbiati previously served as chief executive officer of RingCentral and CFO of Hewlett Pac...
06-24 21:09
FDA细胞与基因治疗监管层集体停职 基因编辑股再遭冲击
智通财经注意到，周五美股盘初，基因编辑公司股价整体持稳，随后随大盘下跌。此前美国FDA生物制品评价与研究中心(CBER)再次突发人事变动——继年初前主任彼得·马...
06-20 21:57
礼来(LLY.US)收购Verve(VERV.US)带来行业提振 基因编辑板块迎上涨
专注于基因疗法的生物科技公司股价上涨，原因是礼来同意以总计不超过 13 亿美元的价格收购位于波士顿的基因编辑初创企业Verve Therapeutics。
06-18 11:28
Lilly-Verve deal sends gene editing stocks higher
Biotech firms focused on gene therapies traded higher after Eli Lilly (NYSE:LLY) agreed to acquire Boston-based gene-editing startup Verve Therapeutics (NASDAQ:VERV) for a total consideration of up to...
06-17 22:29
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Intellia Therapeutics announced promising three-year follow-up data for lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE). A single dose led to a 98% reduction in monthly attack rates, with all 10 patients attack-free for a median of 23 months. Lonvo-z demonstrated a favorable safety profile and no serious adverse events. The Phase 3 HAELO trial has completed screening ahead of schedule, with over half of participants e...
06-15 14:45
